AG Mednet Addresses Cardiovascular Trial Needs for Data Collection and Quality
AG Mednet announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data
AG Mednet announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data into configurable file structures residing either locally or in any of their network shares. By allowing meta-data to be assigned to non-DICOM modalities , this provides for better quality data and less delays for modalities that do not yet conform to the DICOM standard. These include Holter data, spectral domain OCT and others.
For sites participating in AG Mednet-based trials, the imaging submissions remain consistent across the DICOM and non-DICOM data sets. For sponsors, CROs and core labs, non-DICOM modalities are delivered to a file system-based infrastructure, while DICOM modalities are delivered either to a standard DICOM environment, or the same file system-based infrastructure.
You can read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
